By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AmextaFinanceAmextaFinance
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Notification Show More
Aa
AmextaFinanceAmextaFinance
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
AmextaFinance > Investing > GSK Receives Authorization for RSV Vaccine From European Commission
Investing

GSK Receives Authorization for RSV Vaccine From European Commission

News Room
Last updated: 2023/06/07 at 9:01 PM
By News Room
Share
1 Min Read
SHARE
By Christian Moess Laursen

GSK said Wednesday that it has received authorization for its respiratory syncytial virus vaccine Arexvy from the European Commission, the executive body of the EU.

The London-listed pharmaceutical giant said the vaccine will help protect adults 60 years of age or older in 30 European countries from RSV disease for the first time. It is the first time an RSV vaccine for older adults have been granted European marketing authorization, it said.

The first launches are planned ahead of the 2023-24 RSV season which typically starts in the autumn, GSK said.

In Europe, RSV leads to over 270,000 hospitalizations and around 20,000 in-hospital deaths in adults aged 60 or older.

The authorisation is based on phase 3 efficacy data in older adults, GSK said.

Write to Christian Moess Laursen at christian.moess@wsj.com


Read the full article here

News Room June 7, 2023 June 7, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
Elon Musk derides Donald Trump’s tax bill as ‘a disgusting abomination’

Unlock the White House Watch newsletter for freeYour guide to what Trump’s…

New spying claims emerge in Silicon Valley corporate espionage scandal

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

Meta agrees 20-year deal to buy output from Illinois nuclear plant

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

China Overseas Land: Consider Short-Term Challenges And Medium-Term Share Gains (CAOVF)

This article was written byFollowThe Value Pendulum is an Asian equity market…

‘An epic failure’: Russia reels from surprise Ukrainian attack on bomber fleet

Bombers that Russia may never rebuild. A fleet so mauled it may…

- Advertisement -
Ad imageAd image

You Might Also Like

Investing

Why Home Builders Are Bouncing Today—and Why Their Stocks Are Good Buys

By News Room
Investing

This Beaten-Down Industrial Stock Wants to Call America Home. Why It’s Time to Buy.

By News Room
Investing

These 8 Dividend Aristocrats Can Protect Your Portfolio in a Downturn

By News Room
Investing

Some Lenders Benefit From SBA’s Troubled Loan Program

By News Room
Investing

Social Security Is in Turmoil. Should You Lock In Benefits Now?

By News Room
Investing

Hims & Hers Stock Is Due for a Crash Diet. The GLP-1 Surge Is Fading Fast.

By News Room
Investing

Opinion: The stock-market selloff isn’t over yet. Here are 4 reasons why.

By News Room
Investing

With Trump’s tariffs paused, ‘Big Three’ automakers may race to build inventories

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

YOUR EMAIL HAS BEEN CONFIRMED.
THANK YOU!

Welcome Back!

Sign in to your account

Lost your password?